A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disea…
BACKGROUND: Liraglutide, semaglutide and tirzepatide have transformed the management of obesity. However, dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence may limit their long-term he…
BACKGROUND: Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expand…
To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non-diabetic patients with obesity. This multi-site, retrospective, observational study uses data from electronic health records wh…
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction, which contribute to increased disease severity, reduced treatment response, and impaired quality of life. Incretin-based t…
INTRODUCTION: Melanocortin 4 receptor (MC4R) is a G-protein-coupled receptor expressed in the hypothalamus, playing a key role in regulating feeding behavior and energy homeostasis. MC4R is integral to the POMC-MC4R and leptin-MC4R pathways, which co…
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weigh…
BACKGROUND: Semaglutide has demonstrated the ability to reduce the risk of progression to type 2 diabetes in patients with myocardial infarction and overweight or obesity without diabetes. However, implementation of semaglutide treatment in daily cli…
INTRODUCTION: The rapid expansion of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use for weight management and diabetes has raised perioperative questions, particularly regarding delayed gastric emptying and infection risk. Emerging real-worl…
AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise for metabolic and hepatic benefits. This study eva…
Obesity, a global public health crisis driven by complex interactions of genetic, environmental, and behavioral factors, necessitates innovative therapeutic strategies. This review explores the pathogenesis of obesity, emphasizing genetic determinant…
BACKGROUND: Alzheimer's disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping biological mechanisms, and diabetes increases the risk of developing AD. Treatments that modify the course of diabetes, such as metformin and semaglutide, have…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antidiabetic agents that also induce weight loss. Their widespread use has prompted investigation of potential benefits beyond glycemic control, including effects on male sexual a…
BACKGROUND: People with diabetes have an elevated risk of developing depression, anxiety, and suicide. GLP-1 receptor agonists are licensed to treat diabetes and obesity, but data on whether these medications alleviate or exacerbate anxiety, depressi…
BACKGROUND: Peripheral artery disease (PAD) is a prevalent and debilitating complication of diabetes and obesity, yet it remains underrecognized and undertreated. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have shown…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in early T2D management due to their glycemic and weight-reducing effects. However, real-world comparative data in newly diagnosed treatment-naïve individuals rem…
GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have bee…